OTC Markets OTCPK - Delayed Quote USD

Calidi Biotherapeutics, Inc. (CLDWW)

0.0055

-0.0010

(-15.38%)

At close: April 9 at 12:25:00 PM EDT

Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer (“CEO”), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi (“Board”), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. “We are ple

GlobeNewswire 21 hours ago

CLDI

CLDWW
-15.38%
MTEM
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on April 24, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Calidi’s newly appointed Chief Medical Officer, Consultant and Advisor, Guy Travis Clifton, MD, who will share insight into the company’s groundb

GlobeNewswire yesterday

CLDI

CLDWW
-15.38%
Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors

SAN DIEGO, April 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering targeted antitumor virotherapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLD-201. This investigational, allogeneic stem cell-based immunotherapy is set to advance into clinical development for the treatment of solid tumors in adults, focusing on breast

GlobeNewswire 6 days ago

CLDI

CLDWW
-15.38%
Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor

SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor. “With our recently filed IND for a company sponsored, dose escalation trial of CLD-201 in adult patients with solid tumors, Dr. Clifton’s oncology and advisory experience will be i

GlobeNewswire 13 days ago

CLDI

CLDWW
-15.38%
Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced registered direct offering, with a single institutional investor, for the issuance and sale of 3,325,000 shares of the Company’s common stock, and pre-funded warrants to purchase up to 2,728,000 shares of Common Stock. In

GlobeNewswire 23 days ago

CLDI

CLDWW
-15.38%
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial to treat multiple solid tumorsCommencement of recruitment for Phase 1 trial in patients with newly diagnosed high-grade glioma at Northwestern University hospital14 patients enrolled in Phase 1 trial conducted by City of Hope to treat recurrent high-grade glioma SAN DIEGO, March 31, 2025 (GLOBE NEWSW

GlobeNewswire 23 days ago

CLDI

CLDWW
-15.38%
Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it has entered into a definitive securities purchase agreement with a single institutional investor for the purchase and sale of 3,325,000 shares of the Company’s common stock at a per share purchase price of $0.65, and at the election of the investor, in l

GlobeNewswire 26 days ago

CLDI

CLDWW
-15.38%
Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma

SAN DIEGO and LOS ANGELES, March 26, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, and City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, are pleased to jointly announce progress from a phase 1 clinical trial utilizing Calidi’s CLD-101 investigational agent (neural stem cell-based oncoly

GlobeNewswire 28 days ago

CLDI

CLDWW
-15.38%
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / March 14, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program ...

ACCESS Newswire last month

NXL

NXLIW

CLDI
IBN Coverage: Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES - March 11, 2025 (NEWMEDIAWIRE) - Calidi Biotherapeutics (NYSE American: CLDI) announced pos...

NewMediaWire last month

CLDI

CLDWW
-15.38%
Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform

SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced promising preclinical results for its systemic RTNova platform. The platform has successfully delivered transient gene therapy payloads to targeted tumors. Additionally, Calidi's tumor-specific virotherapy has demonstrated efficacy in killing over 60 different tumor cell

GlobeNewswire last month

CLDI

CLDWW
-15.38%
Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored ...

ACCESS Newswire last month

CLDI

CLDWW
-15.38%
OSTX
Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that Northwestern University/Northwestern Memorial Hospital is starting recruitment for the CLD-101 clinical trial of its immunotherapy product. Calidi Biotherapeutics has completed the shipment of the first batch of CLD-101, which comprises allogeneic neural stem cells lo

GlobeNewswire last month

CLDI

CLDWW
-15.38%
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on February 5, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Calidi CFO Andrew Jackson and CSO Antonio F. Santidrian, PharmD. PhD, who will share insight into the company’s groundbreaking cell-based delive

GlobeNewswire 2 months ago

CLDI

CLDWW
-15.38%
Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement

SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that its ending cash balance at December 31, 2024 was approximately $9.6 million. Due to Calidi’s bolstered cash balance and success in recent fundraising, including proceeds resulting from its At-The-Market Offering Agreement (“ATM”), Calidi terminated its Standby Equity

GlobeNewswire 2 months ago

CLDI

CLDWW
-15.38%
Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025

SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that its abstract, titled "Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites", has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting April 25-30, 2025 in Chicago, IL. This significant miles

GlobeNewswire 3 months ago

CLDI

CLDWW
-15.38%
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced public offering of 5,000,000 shares of common stock at $0.85 per share for gross proceeds of approximately $4.25 million. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this offering. The securities describe

GlobeNewswire 3 months ago

CLDI

CLDWW
-15.38%
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it priced its public offering of 5,000,000 shares of common stock at a price of $0.85 per share. The closing of the offering is expected to occur on or about January 10, 2025, subject to satisfaction of customary closing conditions. Ladenburg Thalmann & Co.

GlobeNewswire 3 months ago

CLDI

CLDWW
-15.38%
Calidi Biotherapeutics Announces Proposed Public Offering

SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) in an public offering. All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company. Ladenburg Thalman

GlobeNewswire 3 months ago

CLDI

CLDWW
-15.38%
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, presented data at the International Oncolytic Virotherapy Conference (IOVC) and the Society for Immunotherapy of Cancer (SITC) Annual Meeting to support the targeted capabilities of its proprietary RTNova™ systemic enveloped virotherapy technology. This data supports the potential use of

GlobeNewswire 5 months ago

CLDI

CLDWW
-15.38%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Calidi Biotherapeutics, Inc. (CLDWW)

Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors

Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

IBN Coverage: Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform

Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5

Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement

Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock

Calidi Biotherapeutics Announces Proposed Public Offering

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer